Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neutrophil cytosol factor 1 (NCF1), commonly known as p47phox, is a 47 kDa cytosolic subunit of the multi-protein NADPH oxidase (NOX2) complex, primarily expressed in phagocytic cells such as neutrophils and macrophages [1, 7]. It serves as a critical scaffold protein that organizes the assembly of the active oxidase complex at the plasma or phagosomal membrane upon cellular activation [1, 11]. This process is initiated by the phosphorylation of p47phox, which triggers its translocation and binding to membrane-bound subunits like p22phox [1, 7]. The resulting assembly facilitates the "respiratory burst," producing reactive oxygen species (ROS) like superoxide that are essential for the destruction of ingested pathogens [3, 11]. Mutations in the NCF1 gene are the primary cause of the autosomal recessive form of Chronic Granulomatous Disease (CGD), a condition marked by severe immunodeficiency and chronic inflammation [3, 5, 10]. Conversely, excessive p47phox activity and ROS production contribute to the pathogenesis of various inflammatory, autoimmune, and cardiovascular diseases [1, 15]. Therapeutic development focuses on small-molecule inhibitors that disrupt p47phox translocation or its protein-protein interactions to mitigate oxidative damage in chronic diseases [2, 15]. Additionally, gene therapy approaches are being explored to restore NCF1 function in patients with CGD [13].
Inhibition of p47phox translocation to the membrane, disruption of protein-protein interactions (PPIs) within the NOX2 complex (e.g., p47phox-p22phox binding), and inhibition of p47phox phosphorylation [1, 2, 6, 15].
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neutrophil cytosol factor 1 (p47phox) (NCF1).